Hm Payson & CO Alnylam Pharmaceuticals, Inc. Transaction History

Hm Payson & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$127.18 - $173.91 $27,725 - $37,912	-218 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$159.56 - $209.29 $34,784 - $45,625	218 New	218 $37,000
Q2 2021 Aug 17, 2021	SELL	$128.63 - $176.89 $59,812 - $82,253	-465 Closed	0 $0
Q1 2021 Jun 15, 2021	BUY	$126.83 - $175.69 $32,341 - $44,800	255 Added 121.43%	465 $66,000
Q4 2020 Mar 10, 2021	SELL	$122.97 - $147.0 $6,394 - $7,644	-52 Reduced 19.85%	210 $27,000
Q3 2020 Dec 21, 2020	BUY	$121.19 - $165.49 $31,751 - $43,358	262 New	262 $38,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Hm Payson & CO, based on Form 13F filings with the SEC.

Stay updated on Hm Payson & CO with notifications on news.